Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ankara
Clinical trial register · Turkey

Clinical Trials in Ankara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Turkey and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5418 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5418
Studies in scope
all four open statuses
2461
Recruiting now
open to new participants
548
Lead sponsors
across recruiting studies
Top sites
Ankara 35 Istanbul 34 Izmir 24 Adana 13 Kayseri 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hacettepe University129 AstraZeneca101 Merck Sharp & Dohme LLC91 Ankara City Hospital Bilkent72 Ankara Etlik City Hospital63 Clear sponsor filter
Site location
Ankara35 Istanbul34 Izmir24 Adana13 Kayseri12
All 26 locations
Target enrolment
to

Trials with a site in Ankara

35 of 5418 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Turkey
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
60
Samsun, Ankara
2026-06-26
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Sakarya, Istanbul, Ankara, Izmir, Kocaeli, Samsun
2026-05-27
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Izmir, Ankara, Istanbul, Eskişehir, Samsun, Mersin
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Ankara
2026-01-13
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Istanbul, Ankara
2025-11-03
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Izmir, Ankara, Aydin, Denizli, Mersin, Kecioren Ankara
2025-03-20
Recruiting
Novartis Pharmaceuticals
Phase 3
9
Adana, Ankara, Izmir
2025-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Adana, Ankara, Izmir
2024-12-09
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Istanbul, Ankara
2024-10-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
161
Ankara, Adana
2024-08-15
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Istanbul, Ankara
2024-08-05
Recruiting
Novartis Pharmaceuticals
Phase 3
65
Ankara, Mersin
2024-05-08
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Izmir, Köseköy, Ankara, Mersin
2024-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Sakarya, Ankara, Istanbul, Izmir, Denizli, Antalya, Diyarbakır, Adana
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Ankara, Köseköy
2023-10-27
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Istanbul, Izmir, Köseköy, Kayseri, Ankara, Mersin
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Istanbul, Ankara, Adana
2023-07-11
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Izmir, Ankara, Istanbul, Denizli, Kayseri, Muğla, Eskişehir, Gaziantep
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Ankara, Istanbul
2023-03-02
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Istanbul, Adana, Ankara, Izmir
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Samsun, Ankara, Aydin, Istanbul, Izmir
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Istanbul, Diyarbakır, Ankara
2022-12-06
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Istanbul, Ankara, Izmir
2022-11-21
Recruiting
Novartis Pharmaceuticals
Phase 2
240
Ankara, Istanbul, Kayseri, Bursa, Mersin
2022-08-10
Active, closed
Novartis Pharmaceuticals
Phase 3
95
Adana, Ankara, Istanbul
2022-06-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Ankara, Izmir, Istanbul, Mersin
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Izmir, Istanbul, Bursa, Konya, Ankara, Adana
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
153
Istanbul, Edirne, Ankara, Adana
2021-11-15
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Istanbul, Köseköy, Antalya, Kayseri, Ankara, Mersin
2021-09-20
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Istanbul, Kayseri, Ankara
2021-07-28
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Ankara, Antalya, Edirne, Gaziantep, Izmir, Kayseri, Kocaeli, Mersin
2021-04-09
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Köseköy, Kayseri, Ankara
2019-10-03
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Istanbul, Ankara
2017-08-23
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Istanbul, Kayseri, Ankara, Izmir
2015-03-05
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Samsun, Izmir, Istanbul, Ankara
2013-07-26
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Turkish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-turkey/city/ankara

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Turkey and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,418 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Ankara that also match the filters currently applied.

How many clinical trials are recruiting in Ankara?

18 of the 35 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ankara), 35 studies
PhaseStudiesRecruitingShare
Phase 3261274.3%
Phase 26417.1%
Phase 1/2225.7%
Phase 4102.9%

Most active sponsors

Lead sponsors with the most studies (Ankara)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3518
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.